Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects With MCI and Mild Dementia Due to Alzheimer's Disease.

NCT04498650 is registered in ClinicalTrials.gov with Vivoryon Therapeutics N.V. as lead sponsor.

NCT NCT04498650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04498650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects With MCI and Mild Dementia Due to Alzheimer's Disease.
Lead sponsor
Vivoryon Therapeutics N.V.
Phase
Phase 2
Overall status
Completed
Start date
July 6, 2020
Completion date
January 12, 2024
Enrollment
259 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

early alzheimers disease, mild cognitive impairment due to ad